Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.
Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.
Silexion Therapeutics announced a 1-for-9 reverse share split to maintain Nasdaq compliance and support future growth initiatives.Quiver AI SummarySilexion Therapeutics Corp. has announced a 1-for-9 reverse...
Silexion Therapeutics will present at the Noble Capital Markets Conference on RNAi therapies for KRAS-driven cancers.Quiver AI SummarySilexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotech...
Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.